Avelumab

Therapeutic Avelumab antibody from the original Bavencio® commercial drug

Showing the single result

Filter our product list:
API
Antigen / Target
Therapeutic Areas
Therapeutic Indications
Classes of molecule​s
Isotypes
Expiry Date
Filters Sort results
Product
Antigen
Molecular Class
Drug Brand
Product Concentration
Volume per Vial
Quantity per vial
Storage Temperature
Expiry Date
Price
PD-L1
Monoclonal Antibody
Bavencio®
20 mg/mL
100 µL
2 mg
-80°C
01/2021
236,00 

Not looking for Avelumab?

Search our therapeutic molecules product database

Bavencio® / Avelumab Reference Product

Drug nameBavencio®
INNAvelumab
API typeAvelumab is a human monoclonal IgG1 antibody directed against the immunomodulatory cell surface ligand protein PD-L1 and produced in Chinese hamster ovary cells by recombinant DNA technology.
Pharmacotherapeutic group
Antineoplastic agents, monoclonal antibodies
ATC code
L01XC31
Target of antibody
PD-L1; Synonyms: CD274, B7-H, B7H1, PD-L1, PDCD1L1, PDCD1LG1, PDL1, A530045L16Rik, B7h1, Pdcd1l1,
Pdcd1lg1, Pdl1, RGD1566211
General functionBavencio is used to treat adults with Merkel cell carcinoma (MCC), a rare type of skin cancer when it is metastatic (has spread to other parts of the body).
PD-L1 is found on the surface of MCC cells and helps protect tumour cells from the immune system (the body’s natural defences). Bavencio binds to PD-L1, and blocks this protective effect, allowing the immune system to attack the tumour cells. (Source EMA , package leaflet)
Short descriptionBavencio contains the active substance avelumab, a monoclonal antibody (a type of protein) that attaches to a specific target in the body called PD-L1.
Pharmacodynamic properties
(Mechanism of action; Source EMA document)
Avelumab is a human immunoglobulin G1 (IgG1) monoclonal antibody directed against programmed death ligand 1 (PD-L1). Avelumab binds PD-L1 and blocks the interaction between PD-L1 and the programmed death 1 (PD-1) and B7.1 receptors. This removes the suppressive effects of PD-L1 on cytotoxic CD8+ T-cells, resulting in the restoration of anti-tumour T-cell responses.
Avelumab has also shown to induce natural killer (NK) cell-mediated direct tumour cell lysis via antibody-dependent cell-mediated cytotoxicity (ADCC). (Source: EMA document)
Pharmacodynamic properties (Pharmacodynamic effects; Source EMA document)Avelumab is a human immunoglobulin G1 (IgG1) monoclonal antibody directed against programmed death ligand 1 (PD-L1). Avelumab binds PD-L1 and blocks the interaction between PD-L1 and the programmed death 1 (PD-1) and B7.1 receptors. This removes the suppressive effects of PD-L1 on cytotoxic CD8+ T-cells, resulting in the restoration of anti-tumour T-cell responses.
Avelumab has also shown to induce natural killer (NK) cell-mediated direct tumour cell lysis via antibody-dependent cell-mediated cytotoxicity (ADCC).
Original license holder
Merck Europe B.V.
Marketing authorisation numbers
EU/1/17/1214/001
Marketing authorisation holder
Merck Europe B.V.
Gustav Mahlerplein 102
1082 MA Amsterdam
The Netherlands
Name of the manufacturer of the biological active substance
Merck Serono SA
Succursale de Corsier-sur-Vevey
Chemin du Fenil - Zone Industrielle B,
1804 Corsier-sur-Vevey
Switzerland
Name and address of the manufacturer(s) responsible for batch releaseMerck Serono S.p.A.
Via Delle Magnolie 15 (loc. frazione Zona Industriale)
70026 - Modugno (BA)
Italy
Max shelf life
24 months
Storage conditions
2°C – 8°C
List of excipients
Mannitol
Glacial acetic acid
Polysorbate 20
Sodium hydroxide
Evidentic Support
+49 (0) 30 959 99 8831

Let us know about your inquiry details and we’ll contact you shortly.